Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease

American Journal of the Medical Sciences

Volumn 340, Issue 4, 2010, Pages 259-263

  McCallum, Richard W ^a,b   Zarling, Edwin J ^c   Goetsch, Allen C ^d   Griffin, Carl ^e   Sarosiek, Irene ^a,b   Hejazi, Reza A ^a,b   Doyle, Ralph T ^f   Rotenberg, Keith ^f  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Texas Tech University Health Sciences Center El Paso   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d Huntsville Gastroenterology Associates   (United States)

^e LYNN HEALTH SCIENCE INSTITUTE   (United States)

^f Reliant Pharmaceuticals   (United States)

Author keywords

Bimodal pulsatile release; Controlled release nizatidine; Diabetic gastroparesis; Gastric emptying; Gastric motility; Gastric retention; Gastroprokinetic, Gastroesophageal reflux disease (GERD); Histamine H2 receptor antagonist; Nonulcer dyspepsia, Prokinetic activity; Reflux esophagitis

Indexed keywords

NIZATIDINE; PLACEBO; TECHNETIUM 99M;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; MULTICENTER STUDY; PATIENT IDENTIFICATION; RANDOMIZED CONTROLLED TRIAL; SCINTILLATION CAMERA; SINGLE BLIND PROCEDURE; STOMACH EMPTYING;

EID: 77958014930     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181e9eea2     Document Type: Article

References (24)

1. Parkman HP, Pagano AP, Ryan JP. Ranitidine and nizatidine stimulate antral smooth muscle contractility via excitatory cholinergic mechanisms. Dig Dis Sci 1998;43:497-505.
2. Parkman HP, Urbain JL, Knight LC, et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998;42:243-250
3. Soykan I, Zhiyue L, Jones S, et al. Gastric myoelectrical activity, gastric emptying and correlations with dyspepsia symptoms in patients with gastroesophageal reflux. J Investig Med 1999;45:483-487
4. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reflux. Gastroenterology 1981;80: 285-291
5. Reliant Pharmaceuticals. Prescribing information for Axid® . In: Physician's desk reference. Montvale (NJ): Medical Economics Company; 2000. p. 1570.
6. Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week multicenter, randomized, double-blind study. Am J Gastroenterol 1991;86:1735-1742
7. Sun WM, Hasler WL, Lien HC, et al. Nizatidine enhances the gastrocolonic response and the colonic peristaltic reflex in humans. J Pharmacol Exp Ther 2001;299:159-163
8. Shiomi S, Ishizu H, Kawamura E, et al. Effect of nizatidine on gastric emptying in patients with cirrhosis of the liver. Jpn Pharmacol Ther 2001;29:761-765
9. Zarling EJ. Prokinetic activity of nizatidine: implications for the management of patients with gastroesophageal reflux disease. Clin Ther 1999;21:2038-2046
10. Reliant Pharmaceuticals. NDA 21,442 for nizatidine controlled release (CR) capsules. Montvale (NJ): Medical Economics Company, 2006.
11. Pennington JAT. Bowes and Church's food values of portions commonly consumed, 16th ed. Philadelphia (PA): J.B. Lippincott; 1994.
12. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low-fat meal: establishment of international control values. Am J Gastroenterol 2000;95:1456-1462
13. Chen Y, Caldarelli C, Liu MM, et al. Gastroparesis in chronic dyspepsia and in diabetics with dyspeptic symptoms: diagnostic sensitivity and specificity of gastric scintigraphy [abstract]. Gastroenterology 2001;120:A108.
14. Tougas G, Chen Y, Luo D, et al. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms [abstract]. Gastroenterology 2003;124:A54.
15. Buckles DC, Sarosiek I, McMillin C, et al. Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci 2004;327:1-4.
16. Bytzer P. H2 receptor antagonists and prokinetics in dyspepsia: a critical review. Gut 2002;50(suppl 4):iv58-62.
17. Hansen JM, Bytzer P, Schaffalitzky OB. Placebo controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroeneterol 1998;93:368-374
18. Yamamoto Y, Suzuki T, Hirano M. The effects of nizatidine on the function of esophageal motility in patients with gastroesophageal reflux disease (GERD). Jpn Pharmcol Ther 2000;28:419-424
19. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou A, et al. Comparative study of the H2-receptor antagonists cimetidine, ranitidine, famotidine and nizatidine on the rabbit stomach fundus and sigmoid colon. J Pharmacobiodyn 1992;15:561-565
20. Ueki S, Matsunaga T, Kurimoto T. Nizatidine comparably enhances postprandial gastric motility to existing gastroprokinetics in dogs. Jpn Pharmacol Ther 2000;28:925-930
21. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou A. The excitatory effect of the new histamine H2 receptor antagonist nizatidine (LY 139037) on the guinea pig ileum. J Pharmacobiodyn 1987;10:669-672
22. Paul K, Redman CM, Chen M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther 2001;15:1572-1577
23. Adachi K, Furuta K, Katsube T, et al. Nizatidine and cisapride increase salivary secretion in rats. Dig Dis Sci 2004;49:339-403.
24. Adachi K, Ono M, Kawamura A, et al. Nizatidine and cisapride enhance salivary secretion in humans. Aliment Pharmacol Ther 2002; 16:297-301.